Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
FEMALE
NCT05130801

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-04-22

55

Participants Needed

2

Research Sites

310 weeks

Total Duration

On this page

Sponsors

M

Memorial Sloan Kettering Cancer Center

Lead Sponsor

S

Stryker Instruments

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to find out whether pre-operative mpMRI using additional MRI sequences may improve surgical outcomes by providing more accurate information about the extent and acidity of the tumor than standard MRI, and to see whether the use of the fluorescent imaging agent pHLIP ICG and NIRF imaging during surgery is a safe approach that may allow the surgeon to see the tumor and nearby tissues that contain cancer cells more clearly and remove them completely. During the Phase IIa part of this study, the safe dose of pHLIP ICG will be used that makes it easy for the surgeon to see the tumor and the nearby tissues and structures that may contain cancer cells. This study is the first to test pHLIP ICG in people, and the first to test the use of pHLIP ICG with mpMRI and NIRF imaging in surgery for breast cancer.

CONDITIONS

Official Title

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

Who Can Participate

Age: 18Years +
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or greater
  • Biopsy proven primary breast malignancy (BI-RADS 6)
  • Tumor stage Tis, T1 and T2 with lesion size greater than 1 cm
  • Planned primary surgical treatment with breast conservation
  • No previous treatment for breast cancer
  • ECOG performance status of 0 to 2
Not Eligible

You will not qualify if you...

  • Life expectancy less than 3 months
  • Pregnancy or lactation
  • Known metastatic liver disease, hepatic neoplasms, biliary atresia, chronic liver disease, or cirrhosis
  • Known moderate hepatic impairment (phase I and phase IIa depending on safety profile)
  • Known hypersensitivity to indocyanine green
  • Impaired decision-making capacity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States, 07645

Actively Recruiting

2

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States, 10065

Actively Recruiting

Loading map...

Research Team

C

Clarissa Lin, MD

CONTACT

M

Monica Morrow, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here